Table 1.
List of PEGylated compounds currently in use or approved for use
| Currently Approved Drug | Purpose and/or Effect | Reference |
|---|---|---|
| Krystexxa | Lowers uric acid levels in order to aid in removing gout crystals. | (Hershfield et al. 2014) |
| PEGASYS (peginterferon alpha 2b) | Used with other hepatitis C medicines to treat adults with chronic hepatitis C and certain liver problems. Can be used with ribavirin to treat both adults and children with chronic hepatitis C. | (Wang et al. 2000) |
| Adagen (pegademase) | Modified enzyme used for Enzyme Replacement Therapy (ERT). | (Booth and Gaspar 2009) |
| Oncaspar (pegaspargase) | Given to patients with acute lymphoblastic leukemia as part of a group of chemotherapy treatments. | (Abuchowski et al. 1984) |
| Somavert (pegvisomant) | A prescription medicine for acromegaly, a disease caused by the surplus of growth hormones in the body. The goal is to have a normal IGF-1 level in the blood. | (Thorner 1999; Thorner et al. 1999) |
| Neulasta (pegfilgrastim) | Administered to reduce the risk of infection after strong chemotherapy. | (Johnston et al. 2000) |
| Mircera (CERA; PEG-EPO) | Used to treat symptomatic anaemia associated with chronic kidney disease (CKD). | (Macdougall 2005; Macdougall and Roche 2005) |
| Cimzia (certolizumab) | An injected prescription medication that works to prevent inflammation that may result from an overactive immune system. | (Choy et al. 2002) |
| Macugen (pegaptanib) | Utilized for the treatment of neovascular age-related macular degeneration. | (Bayes et al. 2002) |
| Plegridy (peginterferon beta-1a) | Indicated for the treatment of patients with relapsing forms of multiple sclerosis. | (Pepinsky et al. 2001) |